CAPP2 long term follow up: aspirin protects against hereditary cancer
Session type: Poster / e-Poster / Silent Theatre session
1Newcastle University, UK, 2University of Copenhagen, Denmark, 3St Marys Hospital, Manchester, UK, 4University of Southampton, UK, 5Karolinska Hospital, Stockholm, Sweden, 6The Royal Melbourne Hospital, Melbourne, Australia, 7Birmingham Women's Hospital, UK, 8Jyvskyl Central Hospital, Finland, 9St. Josefs-Hospital Bochum-Linden, Germany, 10Institut Paoli Calmettes, Marseille, France, 11University of Cape Town, South Africa, 12Foundation for Detection of Hereditary Tumours, Leiden, Netherlands, 13Leiden University Medical Center, Netherlands, 14University of Leeds, UK, 15Creighton University School of Medicine, Omaha, USA
The CAPP2 Study evaluated 600mg enteric coated aspirin and/or 30gms of Novelose (resistant starch) in a double blind factorial RCT in 1071 carriers of Lynch syndrome over a treatment period of 1 to 4 years, mean 29 months.
The trial, reported in December 2008 , showed that there was no difference between the treatment and placebo groups for new colorectal neoplasia.